Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BG-C477 |
| Synonyms | |
| Therapy Description |
BG-C477 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting CEACAM5 linked to an undisclosed cytotoxic agent, which potentially induces killing of CEACAM5-expressing tumor cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BG-C477 | BGC477|BG C477 | CEACAM5 Antibody 12 | BG-C477 is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting CEACAM5 linked to an undisclosed cytotoxic agent, which potentially induces killing of CEACAM5-expressing tumor cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06596473 | Phase I | BG-C477 | A Study of BG-C477 in Participants With Advanced Solid Tumors | Recruiting | USA | NZL | AUS | 1 |